Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,794 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neurologic Autoimmune Disease Clear all
Completed Phase 2 Interventional

High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis

NCT00040482
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cyclophosphamide, ATG, MESNA, Radiation therapy
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 6, 2026, 1:19 AM EDT
Terminated Phase 4 Interventional Results available

Natalizumab and Chronic Inflammation

NCT05177718
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Natalizumab 300 MG in 15 ML Injection
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 6, 2026, 1:19 AM EDT
Withdrawn Phase 1 Interventional

Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses

NCT02087813
View directory record Official record
Conditions
Neuromyelitis Optica
Interventions
Alpha1-antitrypsin, methylprednisolone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 6, 2026, 1:19 AM EDT
Withdrawn No phase listed Observational

Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

NCT02419638
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif (IFN β-1a subcutaneous three times per week), Tecifdera (dimethyl fumarate)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 6, 2026, 1:19 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

NCT06782490
View directory record Official record
Conditions
Multiple Sclerosis Spasticity
Interventions
BMS-986368, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 6, 2026, 1:19 AM EDT
Suspended Early Phase 1 Interventional

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

NCT06171152
View directory record Official record
Conditions
Multiple Sclerosis, Long COVID, Long Covid19, Obese, Obesity, Obesity, Morbid, Acute Leukemia in Remission
Interventions
Liraglutide Pen Injector [Saxenda], Medication Diary
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Phase 2 Interventional

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

NCT00071838
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Daclizumab
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 6, 2026, 1:19 AM EDT
Completed No phase listed Observational

Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS

NCT03718247
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Modified Atkins diet
Other
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 6, 2026, 1:19 AM EDT
Recruiting Not applicable Interventional

ECoG BMI for Motor and Speech Control

NCT03698149
View directory record Official record
Conditions
ALS, SCI - Spinal Cord Injury, Stroke, Multiple Sclerosis, Muscular Dystrophies
Interventions
PMT/Blackrock Combination Device
Device
Lead sponsor
Karunesh Ganguly
Other
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Not applicable Interventional

Calorie Restriction in Multiple Sclerosis Patients

NCT02411838
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Calorie restriction
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 6, 2026, 1:19 AM EDT
Not listed Not applicable Interventional

Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis

NCT04073940
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Targeted Ballet Program
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Champaign, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Not applicable Interventional

Whole Health Empowerment for Endotypes of Lupus: Improving Quality of Life in SLE

NCT06720584
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Health coach-led, online support program for people living with lupus
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 6, 2026, 1:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake

NCT01994018
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 6, 2026, 1:19 AM EDT
Completed No phase listed Observational

A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT05363358
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
Not listed
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
6,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 6, 2026, 1:19 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis

NCT00006060
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
standard gadolinium contrast
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
20 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Phase 4 Interventional

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

NCT04377555
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
26
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Not applicable Interventional

Lokomat Treadmill Training Effects on MS Gait

NCT00835835
View directory record Official record
Conditions
Gait, Unsteady, Multiple Sclerosis
Interventions
Body-weight supported treadmill training +/- Lokomat assistance, Usual Care - no active intervention
Other
Lead sponsor
Mount Sinai Rehabilitation Hospital
Other
Eligibility
25 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Not applicable Interventional

Impact of CRISP on Self-Efficacy, Loneliness, and Depression

NCT02030197
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
CRISP Program, Control Group
Behavioral · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 6, 2026, 1:19 AM EDT
Not listed Phase 1Phase 2 Interventional

Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2

NCT04846010
View directory record Official record
Conditions
Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder), Post-Infectious Arthritis, Post-Infectious Polyneuritis, Post-Infectious Parkinsonism, Post-Infectious Hypothyroidism, Post Infectious Osteoarthritis, Anxiety Disorders, Depression, Depression, Anxiety, Depression, Bipolar, Insomnia, GERD, Gastro Esophageal Reflux, Hepatitis, Glomerulonephritis
Interventions
PurWet, FurFat, PurApo, PurPhl, PurClo, PurInf, Smoliv
Combination Product
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 6, 2026, 1:19 AM EDT
Recruiting No phase listed Observational

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

NCT06681623
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Interventions
Ublituximab
Drug
Lead sponsor
Neurology Center of New England P.C.
Other
Eligibility
55 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Foxborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 6, 2026, 1:19 AM EDT
Completed No phase listed Observational

ETNA-MS Device Validation Study

NCT06256731
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Eye-Tracking
Device
Lead sponsor
Innodem Neurosciences
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Phoenix, Arizona • Farmington Hills, Michigan • Owosso, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Not applicable Interventional Results available

Integrating Caregiver Support Into MS Care

NCT02835677
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Behavioral
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 6, 2026, 1:19 AM EDT
Completed Not applicable Interventional

Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis

NCT03177655
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Guided Imagery, Journaling
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 6, 2026, 1:19 AM EDT
Recruiting Phase 2Phase 3 Interventional

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

NCT05491525
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity
Interventions
Vibegron
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Little Rock, Arkansas • Orange, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 6, 2026, 1:19 AM EDT